Advertisement
FATE vs NKTX
Which Stock Would AI Choose? Fate Therapeutics (FATE) vs. Nkarta (NKTX) Stock Comparison
Key Takeaways
- Both FATE and NKTX are clinical-stage biotechs developing "off-the-shelf" engineered cell therapies for autoimmune disease, yet they use different underlying cell platforms.
- FATE has delivered stronger recent momentum, with its shares more than tripling year-to-date, while NKTX has gained roughly half that amount over the same period.
- NKTX holds a larger cash balance with an operating runway into 2029, compared with FATE's runway into 2028.
- Both companies received recent U.S. FDA (Food and Drug Administration) clinical-program updates, but their catalysts differ: FATE secured clearance to advance its FT839 candidate into trials, while NKTX won protocol amendments enabling outpatient dosing.
- Analyst sentiment skews more constructive on NKTX, where the consensus rating is a Strong Buy versus a more mixed, Hold-to-Moderate Buy stance on FATE.
- For deeper coverage of each company's latest developments and daily trading action, explore FATE Major News and FATE Today's Price Move, as well as NKTX Major News and NKTX Today's Price Move.
- To see how automated systems are currently positioning across names like these, explore Trending AI Robots.
Introduction
Investors evaluating the fast-moving cell-therapy segment often encounter two similarly positioned names: Fate Therapeutics and Nkarta. Both are clinical-stage biopharmaceutical companies advancing "allogeneic" (donor-derived, off-the-shelf) cell therapies aimed primarily at autoimmune disease, a market where durable, drug-free remission is a key ambition. This stock comparison is relevant for growth-oriented and event-driven traders who track biotech catalysts such as FDA decisions and clinical data readouts, as well as longer-horizon investors assessing relative performance and market positioning in a speculative corner of healthcare. Although the two firms pursue comparable goals, their platforms, balance sheets, and recent price behavior differ meaningfully.
FATE Overview and Recent Performance
Fate Therapeutics (FATE) is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies built on an induced pluripotent stem cell (iPSC) platform — a method that uses clonal master cell lines to manufacture uniform, off-the-shelf T-cell and natural killer (NK) cell product candidates. Its lead program, FT819, is a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy showing early clinical activity in autoimmune conditions such as systemic lupus erythematosus and lupus nephritis. In recent weeks, the company's shares have been among the stronger performers in the small-cap biotech space, more than tripling year-to-date. A notable catalyst came when the FDA cleared FT839, its multi-antigen dual-CAR T-cell candidate, to begin clinical trials, triggering a sharp single-session advance. The company's operating runway extends into 2028, though its quarterly revenue remains in the low single-digit millions against a persistent net loss.
NKTX Overview and Recent Performance
Nkarta (NKTX) is a clinical-stage biotechnology company advancing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. Its lead candidate, NKX019, is a CD19-targeted CAR-NK therapy being evaluated across multiple autoimmune diseases, including lupus nephritis, systemic sclerosis, and ANCA-associated vasculitis (a group of disorders involving inflamed blood vessels). Recent market activity has been positive but more measured than its peer, with shares up roughly 50% year-to-date. Sentiment improved after the company reached agreement with the FDA on protocol amendments permitting outpatient dosing, optional re-dosing, and the addition of a rheumatoid arthritis cohort — changes designed to broaden patient access. Nkarta ended its most recent quarter with a cash position above $240 million, funding operations into 2029, while its quarterly net loss widened modestly on higher research and development spending.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading systems drawn from a much larger library of AI-powered bots covering thousands of tickers. Because market conditions shift constantly, not every strategy fits every moment; the bots featured in this section are chosen for their current suitability and relevance. The available robots span a wide range of trading styles, timeframes, risk profiles, and performance statistics, and each one targets its own set of tickers. Traders can compare metrics such as historical performance, win rates, and trade frequency to identify approaches that align with their objectives. Whether you follow names like FATE and NKTX or a broader basket of equities, exploring Trending AI Robots can offer a data-driven perspective on current opportunities.
Head-to-Head Comparison
The two companies diverge most clearly in their technological foundations. Fate's iPSC platform enables manufacturing from a renewable, clonal master cell line, which the company argues supports greater scalability and product consistency. Nkarta, by contrast, engineers NK cells derived from healthy adult donors and has prioritized a single-agent, outpatient-friendly dosing profile for its lead asset. These choices create different risk profiles: Fate's approach offers broader pipeline optionality, while Nkarta's strategy emphasizes convenience and a potentially faster path to community-based administration.
On financial positioning, Nkarta holds the stronger cash cushion and longer runway, a meaningful advantage for a cash-burning clinical-stage company. Fate has displayed stronger recent share-price momentum, but its balance sheet is thinner relative to its spending. Analyst consensus also differs: Nkarta carries a Strong Buy rating with a higher average price target, while Fate's coverage is more split between Hold and Buy. Ultimately, traders weighing these names must balance momentum and pipeline breadth against balance-sheet strength and clinical-execution risk.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely lean toward FATE on the basis of stronger trend consistency and recent relative performance, even as it acknowledges NKTX's superior cash runway and more favorable analyst consensus. The AI's assessment would weigh Fate's pronounced upward momentum and expanding clinical catalysts against Nkarta's steadier but less forceful price behavior. Because both names remain highly volatile and catalyst-dependent, the verdict is best understood in probabilistic terms rather than as a definitive ranking, and it may shift quickly as new clinical data and regulatory updates emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a StrongBuy and NKTX is a StrongBuy.
FATE in +3.98% Uptrend, advancing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where FATE advanced for three days, in 214 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for FATE's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FATE as a result. In 85 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for FATE turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 49 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for FATE entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.433) is normal, around the industry mean (3.498). P/E Ratio (-1.748) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (45.045) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. FATE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NKTX's RSI Oscillator climbs out of oversold territory
The RSI Indicator for NKTX moved out of oversold territory on November 11, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 39 of the 41 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 66 cases where NKTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for NKTX just turned positive on November 04, 2026. Looking at past instances where NKTX's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Following a +13.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTX advanced for three days, in 208 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
The 50-day moving average for NKTX moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NKTX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.500) is normal, around the industry mean (3.498). P/E Ratio (-1.088) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FATE | NKTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 62 | 88 | |
P/E GROWTH RATING 1..100 | 13 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NKTX's Valuation (37) in the null industry is in the same range as FATE (50) in the Biotechnology industry. This means that NKTX’s stock grew similarly to FATE’s over the last 12 months.
NKTX's Profit vs Risk Rating (100) in the null industry is in the same range as FATE (100) in the Biotechnology industry. This means that NKTX’s stock grew similarly to FATE’s over the last 12 months.
NKTX's SMR Rating (97) in the null industry is in the same range as FATE (98) in the Biotechnology industry. This means that NKTX’s stock grew similarly to FATE’s over the last 12 months.
FATE's Price Growth Rating (62) in the Biotechnology industry is in the same range as NKTX (88) in the null industry. This means that FATE’s stock grew similarly to NKTX’s over the last 12 months.
FATE's P/E Growth Rating (13) in the Biotechnology industry is in the same range as NKTX (14) in the null industry. This means that FATE’s stock grew similarly to NKTX’s over the last 12 months.
| FATE | NKTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 90% | N/A |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| Advances ODDS (%) | 9 days ago 87% | 9 days ago 84% |
| Declines ODDS (%) | 1 day ago 90% | 3 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FATE’s FA Score shows that 1 FA rating(s) are green while NKTX’s FA Score has 1 green FA rating(s).
- FATE’s FA Score: 1 green, 4 red.
- NKTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FATE’s TA Score shows that 4 TA indicator(s) are bullish while NKTX’s TA Score has 5 bullish TA indicator(s).
- FATE’s TA Score: 4 bullish, 4 bearish.
- NKTX’s TA Score: 5 bullish, 4 bearish.
Price Growth
FATE (@Biotechnology) experienced а -23.21% price change this week, while NKTX (@Biotechnology) price change was -14.45% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.66%. For the same industry, the average monthly price growth was +1.65%, and the average quarterly price growth was -13.40%.
Reported Earning Dates
FATE is expected to report earnings on Mar 01, 2027.
NKTX is expected to report earnings on Mar 25, 2027.
Industries' Descriptions
@Biotechnology (+11.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SMCX | 6.70 | 1.06 | +18.79% |
| Defiance Daily Target 2X Long SMCI ETF (SMCX) | |||
| NXG | 46.59 | 2.34 | +5.29% |
| NXG NextGen Infrastructure Income Fund | |||
| SFLR | 38.93 | 0.36 | +0.93% |
| Innovator Equity Managed Floor ETF (SFLR) | |||
| HRSK | 24.93 | 0.20 | +0.80% |
| Toews Agility Shares Hedged Risk ETF | |||
| SBB | 23.07 | -0.09 | -0.37% |
| ProShares Short SmallCap600 (SBB) | |||